Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab plus minus Ipilimumab.

Trial Profile

Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab plus minus Ipilimumab.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CRUCIAL
  • Most Recent Events

    • 13 Dec 2018 Planned initiation date changed from 1 Sep 2018 to 15 Dec 2018.
    • 25 Jul 2018 Planned End Date changed from 15 Feb 2022 to 15 Apr 2022.
    • 25 Jul 2018 Planned primary completion date changed from 15 Feb 2022 to 15 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top